American Association for Clinical Chemistry

Prenosis Inc. Appoints Leadership Team for Commercialization In Hospitals

Retrieved on: 
Wednesday, October 4, 2023
Infection, Partnership, Society, Research and development, Biomedical Advanced Research and Development Authority, Senior, Sepsis, MSN, Society of Critical Care Medicine, EMR, TED (conference), Robin, Research, Electronic health record, Biomarker, American Thoracic Society, Washington University in St. Louis, Doctor of Philosophy, CIC, Sale, Clinical data standards, Development, Hospital, Verily, MD, Data, Patient, Medicine, Biosafety, RN, Growth, American Association for Clinical Chemistry, Alphabet Inc., BARDA, Medtech, NIH, MDDI, Critical Care Medicine (journal), Management, Nursing, Pharmaceutical industry

CHICAGO, Oct. 4, 2023 /PRNewswire/ -- Prenosis, Inc., an artificial intelligence company enabling precision medicine for abnormal immune responses in acute care, announced today the appointment of Robin Carver, RN, MSN, CIC as Vice President, Health System Engagement, Brian Bray as Vice President, Technology, and an expanded role for Carlos Lopez-Espina as Senior Vice President of Research & Development. Prenosis also announced the addition of Pratik Sinha, MD, PhD, to the company's scientific advisory board.

Key Points: 
  • Prenosis also announced the addition of Pratik Sinha, MD, PhD, to the company's scientific advisory board.
  • Carver and Mr. Bray, executives with over 40 years of combined experience in advancing technology in hospitals, will serve on the executive management team and lead the company's expansion in healthcare systems.
  • "Robin, Brian and Carlos' leadership in commercialization, integration and data will add significant value to the company as we enter the next phase of Prenosis' growth," said Reddy.
  • Prenosis developed its core resource--the world's largest biobank and dataset for decoding abnormal immune responses in acute care--in partnership with over eleven U.S. hospitals.

Harbinger Health Announces Data Demonstrating Its Ability to Detect Early-Stage Multi-Cancer at the AACC Annual Scientific Meeting 2023

Retrieved on: 
Wednesday, July 26, 2023
Abstract, DNA, Methylation, AACC, Cancer, Prognosis, Biomarker, Cancer biomarker, ASCO, American Society of Clinical Oncology, HIV disease progression rates, Reproducibility, Patient, Sequence, Annual general meeting, Biology, Neoplasm, American Association for Clinical Chemistry, Society, PCR, Harbinger, Disease, Pharmaceutical industry, Medical imaging, Nucleic acid thermodynamics

CAMBRIDGE, Mass., July 26, 2023 /PRNewswire/ -- Harbinger Health ("Harbinger," "the Company"), a biotechnology company pioneering the detection of early cancer, today announced data demonstrating the development and advancement of its biology and machine-learning-driven platform, HarbingerHx. The data were presented via three poster abstracts accepted at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo being held in Anaheim, Calif. on July 23-27, 2023.

Key Points: 
  • The data were presented via three poster abstracts accepted at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo being held in Anaheim, Calif. on July 23-27, 2023.
  • "Harbinger is pushing into new frontiers of cancer screening by pairing our proprietary insight into the biology of cancer's origins with our powerful technology platform," said Stephen M. Hahn, M.D., CEO of Harbinger Health.
  • "We aim to turn cancer into a disease that can be managed rather than feared.
  • The abstracts, which are now publicly available, follow Harbinger's recently announced results demonstrating high sensitivity for early-stage multi-cancer detection at the 2023 American Society of Clinical Oncology (ASCO)'s 2023 Annual Meeting.

Microbix Presents Results of STI Test Controls at AACC

Retrieved on: 
Monday, July 24, 2023
CT, AACC, STI, Trichomonas vaginalis, Abbott, Vertically transmitted infection, QAP (Colombia), Emerging, PCR, Point-of-care testing, Infection, Neisseria gonorrhoeae, Mycoplasma, Chlamydia trachomatis, BD, Assay, RUO, Gertrude Pocte Geddes Willis, American Association for Clinical Chemistry, NG, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Medical imaging, Chlamydia, Trichomonas

At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows.
  • Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens.
  • We’re pleased to be offering Microbix QAPs to support clinically-important STI testing – as tools for validation, verification, and training, as external quality assessment samples, and as in-kit controls.”

Co-Diagnostics, Inc. to Host Booth and Discuss Recent Grant Awards at AACC 2023 in Anaheim, CA

Retrieved on: 
Thursday, July 20, 2023
Learning, AACC, COVID-19, Booth, SALT, Sale, Tuberculosis, HPV, American Association for Clinical Chemistry, FDA, Pharmaceutical industry

Co-Dx will also be holding a special milestone presentation and company update to discuss recent grant activity announced earlier this month related to development of the upper respiratory (flu/COVID/RSV), tuberculosis, and HPV tests on its upcoming Co-Dx PCR Home platform.

Key Points: 
  • Co-Dx will also be holding a special milestone presentation and company update to discuss recent grant activity announced earlier this month related to development of the upper respiratory (flu/COVID/RSV), tuberculosis, and HPV tests on its upcoming Co-Dx PCR Home platform.
  • This new platform is currently undergoing clinical evaluations in anticipation of its submission to the FDA and an initial product launch for a COVID-19 test.
  • The presentation will take place in Room 213C at 11:00 AM local time on Tuesday, July 25, and will include Co-Dx CEO Dwight Egan addressing the new grant awards.
  • Attendees interested in learning more are invited to visit the Company at Booth 827.

Thermo Fisher Scientific Launches Scalable Diomni Enterprise Software for Molecular Diagnostics Labs and Test Developers

Retrieved on: 
Thursday, July 13, 2023
Science, Software, Other Science, Biotechnology, Research, Health, Data Management, Technology, AACC, Workflow, Thermo Fisher Scientific, Real-time, Documentation, LIS, American Association for Clinical Chemistry, PCR, Medical device

To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results.

Key Points: 
  • To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results.
  • By connecting workflow steps within one interface, Diomni Enterprise can increase a lab’s ability to dynamically respond to today’s rapidly changing testing environment.
  • Molecular diagnostics clinical labs and kit manufacturers often suffer from antiquated systems that can be hard to scale for increased throughput or expanding test menu.
  • The Diomni Enterprise software will be available for live demonstrations in Thermo Fisher Scientific’s booth #2118 at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo from July 23-27, 2023 in Anaheim, Calif. To learn more about the Diomni Enterprise Software, please visit thermofisher.com/diomni.

NIH Awards Prenosis With Two Grants Totaling $4.8 million to Enable Precision Medicine for Sepsis

Retrieved on: 
Wednesday, July 12, 2023
Infection, Partnership, Society, Housing, Biomedical Advanced Research and Development Authority, Sepsis, Society of Critical Care Medicine, EMR, SBIR, TED (conference), National Institute of General Medical Sciences, Research, Electronic health record, Biomarker, American Thoracic Society, Development, Death, Hospital, Collection, Patient, Data, Machine learning, Algorithm, Medicine, Artificial intelligence, Biosafety, Biology, Mortality, American Association for Clinical Chemistry, WHO, NIGMS, BARDA, Medtech, NIH, MDDI, National Institutes of Health Clinical Center, Critical Care Medicine (journal), Pharmaceutical industry, Medical imaging, Nursing

CHICAGO, July 12, 2023 /PRNewswire/ -- Prenosis, Inc., an artificial intelligence company enabling precision medicine in acute care, announced today that it has been awarded two Phase 2 SBIR grants totaling $4.8M in funding by the National Institute of General Medical Sciences (NIGMS), a division of the National Institute of Health (NIH). The grants will study the use of Prenosis's Immunix™ Artificial Intelligence platform for acute immune states. Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime. The goal is to better understand how patients' health states rapidly evolve in acute care environments.

Key Points: 
  • Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime.
  • The goal is to better understand how patients' health states rapidly evolve in acute care environments.
  • The outcomes of these studies could usher in a new era of predictive diagnostics, clinical decision support tools, improved clinical trials, and precision medicine drugs for sepsis.
  • Prenosis generates deep biological profiles of each patient by measuring critical sepsis biomarkers in its Biological Safety Level 2 lab in Chicago.

Trinity Biotech Announces Q1 2023 Financial Results

Retrieved on: 
Thursday, July 6, 2023
Clinical chemistry, Total, Total addressable market, AACC, Diabetes, HIV, Diagnosis of HIV/AIDS, Tams, Sale, American Association for Clinical Chemistry, Capital, World Health Organization, Units of paper quantity, Growth, FDA, Calibration, Glycated hemoglobin, Pharmaceutical industry, Retail, Video game, Cryptocurrency, Bank

DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2023.

Key Points: 
  • DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2023.
  • Partly offsetting these revenue gains are lower revenues from low margin diabetes instrument deliveries, compared to Q1 2022.
  • Diabetes instrument placements were up approximately 17% in Q1, 2023 vs Q4, 2022.
  • Total revenues for Q1, 2023 were $14.8m which compares to $15.7m in Q1, 2022, a decrease of 5.4% and which were broken down as follows:

Clinical Chemistry Achieves Impact Factor of 9.3; Journal of Applied Laboratory Medicine Debuts at 2.0

Retrieved on: 
Thursday, June 29, 2023
Clinical chemistry, Clarivate, AACC, Diabetes, Journal, Coronavirus, Cancer, Research, COVID, Patient, American Association for Clinical Chemistry, Health, Pharmaceutical industry, PubMed

WASHINGTON, June 29, 2023 /PRNewswire/ -- AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that the journal Clinical Chemistry received an impact factor of 9.3 —the second highest in the journal's history—and the Journal of Applied Laboratory Medicine (JALM) received its first impact factor, of 2.0, according to the newly released 2022 Clarivate Journal Citation Reports.

Key Points: 
  • WASHINGTON, June 29, 2023 /PRNewswire/ -- AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that the journal Clinical Chemistry received an impact factor of 9.3 —the second highest in the journal's history—and the Journal of Applied Laboratory Medicine (JALM) received its first impact factor, of 2.0, according to the newly released 2022 Clarivate Journal Citation Reports.
  • Clinical Chemistry's impact factor places it in the top 3% of 21,522 ranked academic journals and reaffirms its place as the top journal for original research on medical laboratory technology.
  • JALM's impact factor is in line with expectations for a debut journal, and AACC is optimistic it will grow quickly given the journal's highly relevant content focused on the clinical applications of laboratory medicine.
  • JALM debuted in 2016 as an international, peer-reviewed publication dedicated to highlighting the latest applied laboratory medicine research.

New Report: Advancing Kidney Health: A Call to Action

Retrieved on: 
Wednesday, June 28, 2023
National Kidney Foundation, AACC, Creatinine, Culture, EGFR, Medicine, Attention, Biomarker, Black, Language, Transgender, Journal, Patient, NKF, Kidney, Diagnosis, American Association for Clinical Chemistry, Health, Cystatin C, Bias, Kidney disease, Nursing

NEW YORK, June 28, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF) and the American Association for Clinical Chemistry (AACC) continue to challenge the status quo in kidney care through a report titled "Advancing Kidney Health: A Call to Action" for implementation throughout the United States. Published online on June 28th in the Journal of Applied Laboratory Medicine, the report provides in-depth laboratory information on the race-free estimating glomerular filtration rate (eGFR) equations and the biomarkers creatinine and cystatin C as well as implications to patient care, surpassing previous papers that addressed these topics. It also highlights considerations in eGFR values and reporting for transgender and gender-diverse individuals. Many large U.S. clinical laboratories have implemented the 2021 race-free eGFR equations but the National Kidney Foundation's goal is nothing less than complete implementation. "Advancing Kidney Health: A Call to Action" reinforces the profound impact of race-agnostic eGFR equations on kidney disease diagnosis and management decisions, advocating for their adoption to ensure accurate and equitable care for all patients. Additionally, it explores uncharted territory by focusing attention on eGFR values and reporting on transgender and gender-diverse individuals, acknowledging their unique healthcare requirements.

Key Points: 
  • NEW YORK, June 28, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF) and the American Association for Clinical Chemistry (AACC) continue to challenge the status quo in kidney care through a report titled "Advancing Kidney Health: A Call to Action" for implementation throughout the United States.
  • Many large U.S. clinical laboratories have implemented the 2021 race-free eGFR equations but the National Kidney Foundation's goal is nothing less than complete implementation.
  • "Advancing Kidney Health: A Call to Action" reinforces the profound impact of race-agnostic eGFR equations on kidney disease diagnosis and management decisions, advocating for their adoption to ensure accurate and equitable care for all patients.
  • The report's recommendations serve as a vital roadmap for transforming kidney health practices, eliminating disparities, and promoting equitable healthcare outcomes for all individuals affected by kidney diseases.

AACC Elects New Leaders to Serve Terms Starting in August 2023

Retrieved on: 
Tuesday, June 27, 2023
Informatics, MLS, The Ottawa Hospital, BCH, Society, University, AACC, MB, Information technology, Cone Health Women's Hospital, University of Washington Medical Center, National War Finance Committee, Annual, Pathology, MBA, University of Ottawa Faculty of Medicine, Mass spectrometry, Doctor of Philosophy, Science, Harvard Medical School, ASCP, Chemistry, M Health Fairview University of Minnesota Medical Center, CLIA, Vanderbilt University School of Medicine, DLM, Master of Science, Point-of-care testing, Committee, American Association for Clinical Chemistry, Hospital, Health, Committee on Finance, Neurology, Microbiology, Management, Medical device, Brigham

Following this, he will serve successive terms as the association's president from August 2024-July 2025 and as past president from August 2025-July 2026.

Key Points: 
  • Following this, he will serve successive terms as the association's president from August 2024-July 2025 and as past president from August 2025-July 2026.
  • They will take office in August 2023 along with the incoming president of AACC Academy and the incoming chair of the AACC Clinical Laboratory Scientists Council, both of whom will also serve on the board.
  • "I am truly honored that the membership has elected me to serve as the president-elect," said Dr. Killeen.
  • Christopher McCudden, PhD, FAACC, will serve as AACC secretary from August 2023 to July 2026.